# Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-2

Study · id `cardio:ct-nct05836220` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05836220](<https://clinicaltrials.gov/study/NCT05836220>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05836220

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 412 participants.

## Technical summary

Registry record NCT05836220. Randomized; triple masking; primary purpose treatment. Start 2023-05-15 (actual); primary completion 2025-08-05 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 412 participants (enrolled count; ClinicalTrials.gov record NCT05836220, source copy `cardio:ctgov-nct05836220-2025-09-09`, retrieved 2026-10-31)
- Started: 2023-05-15 (actual) (ClinicalTrials.gov record NCT05836220, source copy `cardio:ctgov-nct05836220-2025-09-09`, retrieved 2026-10-31)
- Primary completion: 2025-08-05 (actual) (ClinicalTrials.gov record NCT05836220, source copy `cardio:ctgov-nct05836220-2025-09-09`, retrieved 2026-10-31)
- Completion: 2025-08-05 (actual) (ClinicalTrials.gov record NCT05836220, source copy `cardio:ctgov-nct05836220-2025-09-09`, retrieved 2026-10-31)
- Countries: United States; Bulgaria; Poland; Portugal; Serbia; Spain (ClinicalTrials.gov record NCT05836220, source copy `cardio:ctgov-nct05836220-2025-09-09`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05836220-2025-09-09`, retrieved 2026-10-31)

## The registry's words

- Brief title: Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-2
- Acronym: PATH-2
- Condition: Secondary Hyperparathyroidism
- Condition: End Stage Kidney Disease
- Intervention (Drug): PLS240
- Intervention (Drug): Placebo
- Intervention (Drug): Open-Label Extension PLS240
- Lead sponsor: Pathalys Pharma
- Lead sponsor class: INDUSTRY
- Collaborator: Launch Therapeutics
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)

## Provenance

Content hash: fd201645b1e1854fa5c1e5e7003258a495b49dca123780c8028859abf663dddc
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
